News
DACMA Association donates 12,000 euros for breast cancer research
The Sant Joan Despí association organized an event yesterday in which Dr. Catalina Falo from IDIBELL and ICO presented the project to which the funds will be allocated and where the official delivery of the donation took place.
A study published in ‘NEJM’ expands the range of stroke patients who can benefit from thrombectomy
A study with the participation of the Stroke Unit of the Bellvitge University Hospital and the IDIBELL Neurological Diseases and Neurogenetics group published in the scientific journal The New England Journal of Medicine shows that even stroke patients with extensive areas of brain damage can benefit of being treated with mechanical thrombectomy.
New step towards the deployment of personalized and precision medicine in kidney transplantation
A study led by IDIBELL and the Bellvitge University Hospital allows progress in the personalization of treatment with the immunosuppressant Tacrolimus. The goal of researchers is to be able to limit the time that transplant patients are under- or over-exposed to the drug to minimize the risks of organ rejection and treatment toxicity.
A new study will assess teleassistance for asthma patients
For a year, it will analyze whether patients followed through a mobile application have a better evolution than those treated only in person.
Big success at the 5th IDIBELL Accelerator Meeting Point
This event puts together health and research professionals, biomedicine and biotechnology industry actors, and also innovation experts at a national and international level.
Scientists resolve the hitherto controversially discussed function of complexin in synapses
This study proposes a model that reconciles seemingly contradictory observations regarding the synaptic function of complexin, a protein also involved in certain nervous diseases.
Dr. Teresa Serrano Piñol, new Academic of the Royal Academy of Medicine of Catalonia
Dr. Teresa Serrano has a degree and doctorate in Medicine and Surgery from the University of Barcelona. She has been closely linked to the Bellvitge University Hospital since 1992, and is a member of the TGF-Beta and Cancer research group at IDIBELL and CIBERHED.
Drug repurposing: new opportunities for cancer patients
Computational approach to drug repurposing predicts that a significant 14% of patients could be treated with proven therapies.
Dr. Meritxell Rovira, awarded with the “CRIS de Excelencia” Program to study pancreatic cancer
The recognition granted by the CRIS Foundation against cancer aims to promote and consolidate the careers of researchers with an endowment of up to 1,250,000 euros.